Cycloastragenol, a Triterpenoid Saponin, Regulates Oxidative Stress, Neurotrophic Dysfunctions, Neuroinflammation and Apoptotic Cell Death in Neurodegenerative Conditions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ikram, Muhammad | - |
dc.contributor.author | Jo, Myeung Hoon | - |
dc.contributor.author | Choe, Kyonghwan | - |
dc.contributor.author | Khan, Amjad | - |
dc.contributor.author | Ahmad, Sareer | - |
dc.contributor.author | Saeed, Kamran | - |
dc.contributor.author | Kim, Min Woo | - |
dc.contributor.author | Kim, Myeong Ok | - |
dc.date.accessioned | 2022-12-26T10:00:29Z | - |
dc.date.available | 2022-12-26T10:00:29Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/3155 | - |
dc.description.abstract | Here, we have unveiled the effects of cycloastragenol against A beta (Amyloid-beta)-induced oxidative stress, neurogenic dysfunction, activated mitogen-activated protein (MAP) kinases, and mitochondrial apoptosis in an A beta-induced mouse model of Alzheimer's disease (AD). The A beta-induced mouse model was developed by the stereotaxic injection of amyloid-beta (5 mu g/mouse/intracerebroventricular), and cycloastragenol was given at a dose of 20 mg/kg/day/p.o for 6 weeks daily. For the biochemical analysis, we used immunofluorescence and Western blotting. Our findings showed that the injection of A beta elevated oxidative stress and reduced the expression of neurogenic markers, as shown by the reduced expression of brain-derived neurotrophic factor (BDNF) and the phosphorylation of its specific receptor tropomyosin receptor kinase B (p-TrKB). In addition, there was a marked reduction in the expression of NeuN (neuronal nuclear protein) in the A beta-injected mice brains (cortex and hippocampus). Interestingly, the expression of Nrf2 (nuclear factor erythroid 2-related factor 2), HO-1 (heme oxygenase-1), p-TrKB, BDNF, and NeuN was markedly enhanced in the A beta + Cycloastragenol co-treated mice brains. We have also evaluated the expressions of MAP kinases such as phospho c-Jun-N-terminal kinase (p-JNK), p-38, and phospho-extracellular signal-related kinase (ERK1/2) in the experimental groups, which suggested that the expression of p-JNK, p-P-38, and p-Erk were significantly upregulated in the A beta-injected mice brains; interestingly, these markers were downregulated in the A beta + Cycloastragenol co-treated mice brains. We also checked the expression of activated microglia and inflammatory cytokines, which showed that cycloastragenol reduced the activated microglia and inflammatory cytokines. Moreover, we evaluated the effects of cycloastragenol against mitochondrial apoptosis and memory dysfunctions in the experimental groups. The findings showed significant regulatory effects against apoptosis and memory dysfunction as revealed by the Morris water maze (MWM) test. Collectively, the findings suggested that cycloastragenol regulates oxidative stress, neurotrophic processes, neuroinflammation, apoptotic cell death, and memory impairment in the mouse model of AD.</p> | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Cycloastragenol, a Triterpenoid Saponin, Regulates Oxidative Stress, Neurotrophic Dysfunctions, Neuroinflammation and Apoptotic Cell Death in Neurodegenerative Conditions | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/cells10102719 | - |
dc.identifier.scopusid | 2-s2.0-85116736335 | - |
dc.identifier.wosid | 000713448600001 | - |
dc.identifier.bibliographicCitation | CELLS, v.10, no.10 | - |
dc.citation.title | CELLS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 10 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | ADULT HIPPOCAMPAL NEUROGENESIS | - |
dc.subject.keywordPlus | ASTRAGALOSIDE IV | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | MEMORY | - |
dc.subject.keywordPlus | ROLES | - |
dc.subject.keywordPlus | CREB | - |
dc.subject.keywordAuthor | Alzheimer's disease | - |
dc.subject.keywordAuthor | Amyloid-beta | - |
dc.subject.keywordAuthor | neurogenesis | - |
dc.subject.keywordAuthor | neuroprotection | - |
dc.subject.keywordAuthor | neurodegeneration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0533
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.